BLyS/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept

Shaozhe Cai,Ziwei Hu,Yu Chen,Yuxue Chen,Bingxia Ming,Rongfen Gao,Zhen Li,Cong Ye,Jixin Zhong,Lingli Dong
DOI: https://doi.org/10.1136/ard-2022-223529
IF: 27.973
2023-05-12
Annals of the Rheumatic Diseases
Abstract:IgG4-related disease (IgG4-RD) is a newly recognised fibro-inflammatory clinical entity with multiorgan involvement. Although most patients with IgG4-RD respond well to glucocorticoids, they have limited treatment options for disease control and high relapse rates were reported during long-term treatment.1 We report here a series of IgG4-RD cases treated with telitacicept, a novel bioagent (TACI-immunoglobin fusion protein) simultaneously targeting B cell maturation signals BLyS (BAFF) and APRIL,2 in the absence of long-term glucocorticoids. A 54-year-old man, who was diagnosed with IgG4-RD in 2017, presented in our department with re-enlarged bilateral submandibular glands, parotid glands and 12 lymph nodes after withdrawal of glucocorticoids (with a new onset of renal involvement). His 2019 American College of Rheumatology/European League Against Rheumatism classification criteria (ACR/EULAR)3 classification criteria score was 41 and IgG4-RD Responder Index (RI)4 was 12 at admission. After the discontinuation of glucocorticoids within 1 week,...
rheumatology
What problem does this paper attempt to address?